Elemental & Genotoxic Impurities to be Held From 26th-28th November

MUMBAI, November 17, 2014 /PRNewswire/ --

In November 2013, the ICH M7 Guideline on Assessment and Control of DNA Reactive Impurities reached the Step 4 of the ICH Process and will now enter the implementation period (Step 5) in the year 2015. These recent changes around ICH M7 guidelines related to genotoxic impurities and USP <232> <233> and ICH Q3D related to elemental impurities has made it a must for the Indian pharma companies to convince the regulatory authorities to achieve global regulatory compliance.

     (Logo: http://photos.prnewswire.com/prnh/20141117/10110997)
     (Logo: http://photos.prnewswire.com/prnh/20130226/599595-c)

Looking at the criticality of the subject, CPhI Conferences is organising a 3-day strategic conference on Elemental & Genotoxic Impurities from 26^th - 28^th November, 2014 at the Hyatt Regency in Mumbai.

The key focus of this forum will be discussing the various regulatory updates on ICH and USP guidelines and cost effective solutions for identification, analysis and control of elemental and genotoxic impurities in drug substances and drug products at an early stage to ensure global regulatory compliance.

Visit the website at www.drugimpuritiesconference.com  or click here to download the complete agenda

The experts speaking at the conference include:

1. Dr. Sumit Sen, Chemist (Instrument Specialist), USFDA
2. Dr Vinod Kansal, President R&D, Teva
3. Dr. Bhaskar Gollapudi, Senior Managing Scientist, Exponent's Health Sciences Center for Toxicology and Mechanistic Biology, US
4. Dr. Chandrika B. Rao, Ex. Director Discovery Informatics, Piramal Healthcare
5. Dr. Venkat Manohar, Director, Indian Institute of Chromatography and Mass Spectrometry (IICMS)
6. Mr. Andrew Teasdale, Principal Scientist, Astrazeneca.

In addition to the critical issues being addressed, the conference, organised by UBM India, will also provide a platform for extensive networking with industry peers and provide knowledge on the cost effective analytical solutions which would become Indian pharma companies' top most priorities to ensure long-term sustainability.

About UBM India

UBM India is India's leading live media and events company that engages people and enriches businesses. UBM India provide the industry with platforms that bring together buyers and sellers from around the world, through a portfolio of exhibitions, content led conferences and seminars, tech media, live events, data services and powerful media brands. UBM India hosts over 20 large scale exhibitions and 40 conferences across the country every year, thereby enabling trade across multiple industry verticals. A UBM Asia Company, UBM India has offices across Mumbai, New Delhi, Bangalore and Chennai. UBM Asia is owned by UBM plc which is listed on the London Stock Exchange. UBM Asia is the leading exhibition organiser in Asia and the biggest commercial organiser in mainland China, India and Malaysia. For further details, please visit www.ubmindia.in

Media Contact: Mustafa Nalwalla, [email protected], +91-9820999303, +91-22-61727067, Marketing Manager, UBM India